Friday, October 2, 2026
25.3 C
Bengaluru

Covid-19 Impact on Indian Pharma Revenues, Field Force, Doctors – Sunil Attavar, CMD Group Pharma

This is the third and final part of MedicinMan interview with Sunil Attavar, CMD, Group Pharma and President, KDPMA

MedicinMan: Are there any estimates of what the overall business impact will be in terms of revenues of pharma companies?

 At this moment it is very difficult to estimate the impact but it will not be uniform across companies.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Why Is the World’s Pharmacy Failing to Protect Patients from Harm?

This MedicinMan Intelligence Report follows a disturbing trail—from Arun...

Shakul Srivastava has been appointed as Senior Vice President at Indian Immunologicals Limited.

With over three decades of experience in the pharmaceutical...

The Rx–Outcomes Dichotomy: India Has Iron Tablets. Why Does Anaemia Persist?

India’s anaemia challenge is not simply about access to...

10 Years of Pharma M&A — Who’s Really Benefited?

Pharmaceutical M&A is usually discussed in the language of...

What’s Killing Patients? Cancer or Rigged Drug Prices?

The disease is real. So is the markup. Confusing...

Topics

spot_img

Related Articles

spot_imgspot_img